Clinical trials: Anti-Glaucoma Medications
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost.
- Trial name
- NCT01060579
- Testing
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Where
- 18 sites in United States
- Volunteers
- 217 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open Angle Glaucoma
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT07082816
- Testing
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
- Where
- 30 sites in United States
- Volunteers
- 489 people
- Sponsor
- Alcon Research
Glaucoma Treatment Using Focused Ultrasound
UCP Glaucoma Treatment for Primary Glaucoma in China
To collect safety and efficacy data on Ultrasound Cycle Plasty treatment (UCP) in primary glaucoma asian patients.
- Trial name
- NCT04145830
- Testing
- Ultrasound Cyclo Plasty (UCP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Glaucoma
Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients
The purpose of the this study is to collect safety and efficacy data on Focused Ultrasound treatment (UCP procedure) in open angle glaucoma patients without previous glaucoma surgery.
- Trial name
- NCT02789293
- Testing
- EyeOP1 device
- Where
- 4 sites in Belgium, Israel and 2 more
- Volunteers
- 80 people
- Sponsor
- EyeTechCare
Open-Angle Glaucoma
Collaborative Initial Glaucoma Treatment Study (CIGTS)
To compare the long-term effect of treating newly diagnosed open-angle glaucoma with standard medical treatment versus filtration surgery.
- Trial name
- NCT00000149
- Testing
- Beta Blocker, Trabeculectomy, Argon Laser Trabeculoplasty
- Sponsor
- National Eye Institute (NEI)
Ocular Hypertension, Open-angle Glaucoma
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.
- Trial name
- NCT01699464
- Testing
- AR-12286 Ophthalmic Solution 0.7%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Volunteers
- 211 people
- Sponsor
- Aerie Pharmaceuticals
POAG, Primary Open Angle Glaucoma
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with primary open angle glaucoma.
- Conditions
- POAG, Primary Open Angle Glaucoma, Ocular Hypertension
- Trial name
- NCT02792803
- Testing
- Xalatan, Apo-Latanoprost, Co-Latanoprost
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr. David Yan
Glaucoma
VW-50 Feasibility Study
An investigator-initiated 10-participant Feasibility Study to assess a novel glaucoma drainage implant, VW-50.
- Trial name
- NCT07730424
- Testing
- Surgical implantation of VW-50
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Melbourne Eye Specialists